April 4, 2013
/PRNewswire/ -- Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Receptos. The number of shares to be offered and the price range for the offering have not yet been determined.
Credit Suisse Securities (
) LLC, Leerink Swann LLC and BMO Capital Markets are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences is acting as a co-manager. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Credit Suisse Securities (
) LLC, Attention: Prospectus Department, One Madison Avenue,
New York, NY
10010, Telephone: (800) 221-1037, Email:
; from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
02110, Telephone: (800) 808-7525, Email:
; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square,
New York, NY
10036, Telephone: (800) 414-3627, Email:
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.